NBNadeen Balousha

Nadeen Balousha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nadeen Balousha has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Olfactory dysfunction occurrence, undetected hazards, and relationships in Parkinson’s disease: a multicentre study

    by Ahmed Ramzi, Mufreh Amin, Mahmoud Samir, Rovan Rouby, Dalia Elnady, Mohamed Srour, Hanan Amer, Esraa Elsaeed Elnawagy, Ahmad Farag Ibrahim El-Adawy, Mostafa Meshref, et al.

    Background: The study sought to quantify and stratify olfactory dysfunction (OD) in Parkinson's disease (PD) using a brief multi-item tool and to explore demographic and clinical patterns in a broad cohort from Egypt. We conducted a multicentre cross-sectional study across neurology clinics. OD was assessed using Vernetti’s Hyposmia Rating Scale, which was translated into Egyptian, integrated into the study survey, piloted, and psychometrically tested. Analyses included multivariable adjusted models. Results: We enrolled 434 patients with PD. Median age at diagnosis was 55 years (IQR 45 to 62), and two thirds were diagnosed within 1 year of motor symptom onset. Family history of PD (20%) was associated with motor symptoms appearing years earlier. Smoking, however, was associated with a later age. More than half of all patients had OD (58.5%), which was typically gradual and either persistent or worsening. The six-item scale identified 34.3% of OD cases that a single global question would have missed ( p < 0.001). In adjusted models, OD showed only a small association with education. A quarter of patients reported never detecting nearby gas leaks even when alerted. Loss of food-smell distinction closely tracked OD status ( p < 0.001). Most had at least one other non-motor symptom (NMS). Conclusions: A majority of patients had OD. It was the prevailing NMS and correlated with overall burden. PD patients in this cohort had a younger age at disease onset and a high rate of family history linked to an even earlier onset. The interval from initial motor complaints to diagnosis appeared comparable to that reported in advanced healthcare settings worldwide. For hyposmia assessment, the brief scale improved identification and flagged safety risks and quality-of-life implications. The hyposmia-related hazards warrant further investigation to objectively test hazard detection and risk-reduction measures.

  • Pentoxifylline uses in inner ear diseases

    by Ahmed Ramzi, Subhia Maya, Nadeen Balousha, Mufreh Amin, Rovan Ahmed Rouby, Ghalia Aljarrah, Dalia Gamal Elnady, Ahmed Samir, Thoria Ibrahim Essa Ghanm, Zahraa Natheer Bhaya, et al.

    Background Labyrinth or the inner ear consists of the cochlea (for hearing) and vestibular system (for balance), with disorders affecting hearing, balance, or both, and symptomatology including hearing loss, tinnitus, and vertigo. Regulatory-approved medications for inner ear diseases are rare worldwide relative to the frequency of those diseases. There are no FDA-approved medications for any inner ear disease. This is due to multiple reasons, including the lack of conclusive evidence for various drugs that have been investigated. We aim to contribute to the review endeavor by addressing pentoxifylline (PTX), a medication that has been studied for cochlear and vestibular disorders, yet its efficacy and safety have not been systematically reviewed in a publication. Methods More than a dozen databases from around the globe were systematically searched, including PubMed, EMBASE, Scopus, Web of Science, Cochrane/CENTRAL, ScienceDirect, Google Scholar, Europe PMC, ICTRP, ClinicalTrials.gov, EU-CTR, PsycInfo, LILACS, WPRIM, IBECS, SciELO, CNKI, VIP, and Wanfang, to methodically compile experimental and analytical studies. Search results are up to January 2025. This work focused on workable reports in which PTX had distinct or attributable results and organized them into overarching categories of vertigo, hearing loss, and tinnitus. Results Forty studies, including 15 randomized controlled trials (RCTs), were included. Each condition was addressed in seven RCTs, with some overlap. Studies on inner ear vertigo reported significant outcomes for PTX. A large proportion of the literature involved idiopathic sudden sensorineural hearing loss (ISSNHL), but its results were mixed. Studies on tinnitus suggest that PTX has similar efficacy to Ginkgo biloba extract and corticosteroids, two of the most prescribed medications. Adverse events were generally mild and rarely necessitated discontinuation. Conclusion Pentoxifylline could improve inner ear vertigo and tinnitus. In ISSNHL, results are inconsistent in the context of spontaneous recovery rates, albeit leaning toward ineffectiveness. Over a variety of regimens, it sustained good safety. The rigor and designs of the reports could not produce robust recommendations.


  • Open Access

    Effects of the anti-inflammatory pentoxifylline on psychiatric and neuropsychiatric conditions: exploring various off-label utilities with meta-analyses

    by Ahmed Ramzi, Subhia Maya, Nadeen Balousha, Mufreh Amin, Robert Charles Powell, Mostafa Ramzi Shiha

    Background: Chronic inflammation has been linked to many psychiatric disorders, and therefore, pertinent anti-inflammatory therapies have been empirically evaluated for management. An enduring example of long-term safety, attainability, and versatility has been pentoxifylline (PTX). PTX is a phosphodiesterase inhibitor that modulates inflammatory mediators and affects most blood components and the blood vessels. Methods: Major databases were systematically searched to identify randomized controlled trials (RCTs) on PTX in psychiatric and neuropsychiatric disorders until September 25, 2024. Results: 21 RCTs were included. Five studies evaluated clinical depression: four on major depressive disorder (MDD) and one on bipolar patients experiencing treatment-resistant depression. PTX significantly reduced depressive symptoms in MDD in the four double-blind, randomized, placebo-controlled trials, with the three studies combining PTX and SSRIs showing statistically significant improvements in response rates. Ten RCTs on cognitive impairment reported beneficial effects, particularly in vascular dementia. Meta-analyses support its efficacy in reducing depressive symptoms, cognitive decline, asthenia, and inflammatory markers. Conclusion: Exploring the effects of PTX on psychiatric and neuropsychiatric conditions has provided considerable support for its utility across various disorders, most notably in moderate to severe major depressive disorder (as adjunctive therapy with SSRIs) and cognitive impairment in vascular dementia (as monotherapy). Relevantly, the potential of PTX across a wide range of conditions might prove beneficial in cases of co-occurrence.


  • Open Access

    Pentoxifylline in COVID-19 and considerations for its research in long COVID

    by Ahmed Ramzi, Subhia Maya, Nadeen Balousha, Mufreh Amin, Mostafa Ramzi Shiha

    Introduction: Pentoxifylline (PTX) affects most blood components and the blood vessels, potentially modulating various conditions. Due to its impact on markers linked to COVID-19 severity, research has explored PTX for acute COVID-19. Following the widespread administration of COVID-19 vaccinations, there has been a notable and consistently growing increase in research focusing on long COVID. Consequently, our examination of relevant acute COVID-19 data shall additionally be contextualized into long COVID research. Methods: Various Databases were searched until July 2024 for all primary clinical studies on Pentoxifylline (PTX) in COVID-19. Results: Studies were on acute infection with SARS-CoV-2 where PTX was an adjuvant to standard therapy for ethical and practical reasons under the circumstance. PTX generally reduced hospitalization duration and improved some inflammatory markers, but its impact on mortality was inconsistent. Adverse events were minimal. Meta-analysis revealed a significant reduction in hospitalization duration. Conclusion: This systematic review and meta-analysis suggest that adding pentoxifylline (PTX) to standard COVID-19 therapy may significantly reduce hospitalization duration and improve some inflammatory markers. However, its impact on mortality rates is inconclusive. Adverse events are minimal. PTX can be favorable as an add-on in managing acute COVID-19 and could reduce the risk of long COVID, as well as assist in managing many of its most common symptoms.


  • Open Access

    Subcutaneous immunoglobulins (SCIG) for chronic inflammatory demyelinating polyneuropathy (CIDP): A comprehensive systematic review of clinical studies and meta-analysis

    by Ahmed Ramzi, Subhia Maya, Nadeen Balousha, Haneen Sabet, Ahmed Samir, Merna Raafat Roshdy, Ghalia Aljarrah, Sireen Saleh, Ahmed Kertam, Ibrahim Serag, et al.

    Background: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) presents significant treatment challenges due to its chronic nature, varied clinical presentations, and rarity. Subcutaneous immunoglobulin (SCIG) has emerged as a maintenance therapy, offering potential advantages in administration and patient experience over the previously recognized intravenous immunoglobulin (IVIG). Methods: We included all clinical studies involving CIDP patients treated with SCIG from eleven databases up to March 2024. Results: 50 clinical studies were included in the systematic review, with 22 involved in the meta-analysis. These studies offer clinical data on around 1400 CIDP patients. Almost all studies considered SCIG a maintenance therapy, with the majority of results suggesting it as a viable substitute that may offer comparable or enhanced advantages. Studies covered aspects such as efficacy, safety, quality of life, practicality, economic evaluation, and patient preference. Meta-analysis showed SCIG significantly improved muscle strength and sensory function, had fewer and milder side effects, reduced relapse rates, and received a strong preference. Conclusions: Findings suggest that SCIG for CIDP maintenance not only provides a more feasible alternative, with economic evaluations showing considerable cost reductions over time, and patient preference for SCIG being pronounced, but may also deliver comparable or superior health outcomes. Ongoing research lines on formulations, techniques, and direct comparative studies are critical to further illuminate, enhance, and expand SCIG's role in treatment.